standard dose indomethacin
Small molecule
standard dose indomethacin is one of 41 small molecule programs targeting Pancreatitis. It is currently in development.
1
Indications
2
Total Trials
1
Active Trials
40
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
70 competitors in Pancreatitis
#DrugCompanyPhaseTrials
1Cysteine Hydrochloride
NovartisApproved
Doribax
ShionogiApproved
Nitrostat
VViatris Specialty LLC
Approved
Avycaz
PPhiladelphia Eye Associates
Approved
Trental
VValidus Pharmaceuticals
Approved
Acetadote
AArbor Pharmaceuticals, Inc.
Approved
Cymbalta
Alnylam PharmaceuticalsPhase 3
Octreotide
Johnson & JohnsonPhase 3
Zofran
NovartisPhase 3
Resveratrol
NNational Cancer Institute (NCI)
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Pancreatitis2 trials
Low-Dose vs Standard-Dose Indomethacin for Preventing Post-ERCP Pancreatitis
Recruiting·—·Phase 4·NCT07088757·1,366 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for standard dose indomethacin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Company
- IIndiana University